1, 5-7 Specifically, increased expression of PDGFRα has been found in about 65%-80% cases of patient HCC versus adjacent non-tumorous tissues. 2, 5, 6, 8 Overexpression of PDGFRα in vascular endothelial cells was found to be positively associated with metastasis and recurrence of HCC.9 Thus, PDGFRα is considered as an “oncogene” and a new target for the treatment of HCC.1 However, whether modulation of PDGFRα expression in hepatocytes would have any impacts on liver pathophysiology remains largely unknown. The gene discussed is PDGFRA; the disease is hepatocellular carcinoma.